| pubmed-article:21029400 | rdf:type | pubmed:Citation | lld:pubmed |
| pubmed-article:21029400 | lifeskim:mentions | umls-concept:C0016514 | lld:lifeskim |
| pubmed-article:21029400 | lifeskim:mentions | umls-concept:C0021311 | lld:lifeskim |
| pubmed-article:21029400 | lifeskim:mentions | umls-concept:C0003451 | lld:lifeskim |
| pubmed-article:21029400 | lifeskim:mentions | umls-concept:C0085112 | lld:lifeskim |
| pubmed-article:21029400 | lifeskim:mentions | umls-concept:C0026336 | lld:lifeskim |
| pubmed-article:21029400 | lifeskim:mentions | umls-concept:C0220825 | lld:lifeskim |
| pubmed-article:21029400 | lifeskim:mentions | umls-concept:C1527148 | lld:lifeskim |
| pubmed-article:21029400 | lifeskim:mentions | umls-concept:C0439611 | lld:lifeskim |
| pubmed-article:21029400 | pubmed:issue | 6 | lld:pubmed |
| pubmed-article:21029400 | pubmed:dateCreated | 2010-11-12 | lld:pubmed |
| pubmed-article:21029400 | pubmed:abstractText | Recent European guidelines facilitate the use of emergency vaccines during outbreaks of foot-and-mouth disease. Antiviral drugs could be used as a complementary measure. This study aimed at developing a small animal model to assess the in vivo activity of early antiviral lead molecules with anti-foot-and-mouth disease virus (FMDV) activity in vitro. In a first attempt, several FMDV strains were titrated in Balb/c mice. Inoculations with O? Manisa or C? Noville did not induce clinical disease, whereas Asia1 Shamir induced death too rapidly [i.e. within 4 days post-inoculation (dpi)]. Therefore, we switched to severe combined immunodeficient mice which are frequently used as a model for viral infections and experimental therapeutics. Strain O? Manisa did not induce clinical disease, but titrations with A?? Iraq, C? Noville or Asia1 Shamir resulted in virus-induced morbidity (including respiratory problems and weight loss) with subsequent mortality. Inoculations with strain A?? Iraq resulted in a reproducible mean time of death of 6 dpi (this was shorter for the other strains). In this newly developed rodent model, strain A?? Iraq seems the most suited to assess the in vivo anti-FMDV activity of selective inhibitors of FMDV. | lld:pubmed |
| pubmed-article:21029400 | pubmed:language | eng | lld:pubmed |
| pubmed-article:21029400 | pubmed:journal | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:21029400 | pubmed:citationSubset | IM | lld:pubmed |
| pubmed-article:21029400 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:21029400 | pubmed:status | MEDLINE | lld:pubmed |
| pubmed-article:21029400 | pubmed:month | Dec | lld:pubmed |
| pubmed-article:21029400 | pubmed:issn | 1865-1682 | lld:pubmed |
| pubmed-article:21029400 | pubmed:author | pubmed-author:NeytsJJ | lld:pubmed |
| pubmed-article:21029400 | pubmed:author | pubmed-author:De ClercqKK | lld:pubmed |
| pubmed-article:21029400 | pubmed:author | pubmed-author:LefebvreD JDJ | lld:pubmed |
| pubmed-article:21029400 | pubmed:copyrightInfo | © 2010 Blackwell Verlag GmbH. | lld:pubmed |
| pubmed-article:21029400 | pubmed:issnType | Electronic | lld:pubmed |
| pubmed-article:21029400 | pubmed:volume | 57 | lld:pubmed |
| pubmed-article:21029400 | pubmed:owner | NLM | lld:pubmed |
| pubmed-article:21029400 | pubmed:authorsComplete | Y | lld:pubmed |
| pubmed-article:21029400 | pubmed:pagination | 430-3 | lld:pubmed |
| pubmed-article:21029400 | pubmed:meshHeading | pubmed-meshheading:21029400... | lld:pubmed |
| pubmed-article:21029400 | pubmed:meshHeading | pubmed-meshheading:21029400... | lld:pubmed |
| pubmed-article:21029400 | pubmed:meshHeading | pubmed-meshheading:21029400... | lld:pubmed |
| pubmed-article:21029400 | pubmed:meshHeading | pubmed-meshheading:21029400... | lld:pubmed |
| pubmed-article:21029400 | pubmed:meshHeading | pubmed-meshheading:21029400... | lld:pubmed |
| pubmed-article:21029400 | pubmed:meshHeading | pubmed-meshheading:21029400... | lld:pubmed |
| pubmed-article:21029400 | pubmed:meshHeading | pubmed-meshheading:21029400... | lld:pubmed |
| pubmed-article:21029400 | pubmed:meshHeading | pubmed-meshheading:21029400... | lld:pubmed |
| pubmed-article:21029400 | pubmed:meshHeading | pubmed-meshheading:21029400... | lld:pubmed |
| pubmed-article:21029400 | pubmed:meshHeading | pubmed-meshheading:21029400... | lld:pubmed |
| pubmed-article:21029400 | pubmed:year | 2010 | lld:pubmed |
| pubmed-article:21029400 | pubmed:articleTitle | Development of a foot-and-mouth disease infection model in severe combined immunodeficient mice for the preliminary evaluation of antiviral drugs. | lld:pubmed |
| pubmed-article:21029400 | pubmed:affiliation | Unit of Vesicular and Exotic Diseases, Virology Department, CODA-CERVA-VAR, Veterinary and Agrochemical Research Centre, Groeselenberg, Brussel, Belgium. dalef@var.fgov.be | lld:pubmed |
| pubmed-article:21029400 | pubmed:publicationType | Journal Article | lld:pubmed |
| pubmed-article:21029400 | pubmed:publicationType | Research Support, Non-U.S. Gov't | lld:pubmed |
